期刊文献+

棒状杆菌ps1产生广谱抗真菌活性物质的初步研究

An Antifungal Compound Produced by Corynebacterium spp .
下载PDF
导出
摘要 棒状杆菌ps1能产生广谱抗真菌活性物质 ,对其活性物质的抗菌谱、产生条件和部分特性进行了初步研究。棒状杆菌ps1产生的活性物质psch1对白色念珠菌、丝核菌、镰刀菌等多种真菌均有强烈抑制作用 ,并具有良好选择性。活性物质psch1耐热性好 ,pH改变对其活性影响较明显 ,酸性环境有利于其稳定但在碱性条件下容易失活。 A bacterium which produced antifungal compound from cultured broth was isolated from the intestinal tract of an insect. The organism was initially ide ntified as Corynebacterium spp. The compound has broad spectrum of antifunga l activities. It is effective against Candida albican, Verticillum alboatrum, Fusarium spp., Rhodotorula rubra, Aspergillus niger, Aspergillus flavus, Rhi zopus nigricans, Aspergillus ficuum, Rhixoctonia solaai and Trichoderma viri de. It is stable at high temperature. After treatment at 121 ℃ for 30 min onl y 35% of the total activity is lost. However, pH has profound effect on the acti vity. It is stable in acidic conditions and unstable in alkaline conditions.
出处 《中山大学学报(自然科学版)》 CAS CSCD 北大核心 2003年第3期120-121,共2页 Acta Scientiarum Naturalium Universitatis Sunyatseni
基金 广东省自然科学基金资助项目 ( 0 0 12 14)
关键词 抗真菌 棒状杆菌 antifungal Corynebacterium
  • 相关文献

参考文献3

  • 1盛春泉,季海涛,张万年.新型抗真菌药物的研究进展[J].国外医学(药学分册),2001,28(6):347-351. 被引量:11
  • 2DOMINIQUE S. Integrated antifungal drug discovery in Candida albicans [ J ]. Nature Biotechnology, 2001, 19:212-213.
  • 3DIDOMENICO B. Novel antifungal drugs [ J]. Current Opinion in Microbiology, 1999,2(5) : 509- 515.

二级参考文献25

  • 1Dixon DM, McNeil MM, Cohen ML, et al. Fungal infections: a growing threat[J]. Public Health Rep, 1996, 111(3) :226 - 235.
  • 2Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development[J]. Annu Rev Microbiol, 1994, 48(3):471 -497.
  • 3Marco F, Pfaller MA, Messer SA, et al. Activity of MK991(L-743872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp[J]. Diagn Microbiol Infect Dis, 1998, 32(1):33 - 37.
  • 4Ernst EJ, Klepser ME, Ernst ME, et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods[J]. Diagn Microbiol Infect Dis, 1999, 33(2):75-80.
  • 5Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii[J]. Antimicrob Agents Chemother, 1998, 42(8): 1985 - 1989.
  • 6Graybill JR, Najvar LK, Montalbo EM, et al. Treatment of histoplasmosis with MK-991 (L-743872)[J]. Antimicrob Agents Chemother , 1998, 42(1) :151 - 153.
  • 7Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent. FK463, against a variety of clinically important fungi[J]. Antimicrob Agents Chemother, 2000, 44(1):57-62.
  • 8Maesaki S, Hossain MA, Miyazaki Y, et al. Efficacy of FK463, a (1,3)-beta- D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice [J]. Antimicrob Agents Chemother, 2000, 44 (6): 1728 -1730.
  • 9Gunawardana G, Rasmussen RR, Scherr M, et al. Corynecandin: anovel antifungal glycolipid from Coryneum modonium[J]. J4ntibiot(Tokyo), 1997, 50(10):884- 886.
  • 10Chiba H, Kaneto R, Agematu H, et al. Mer-WF3010, a new member of the papulacandin family. Ⅱ . Structure determination[J]. J Antibiot(Tokyo), 1993, 46(2):356-358.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部